Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | AMY2A | P04746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Griffonin SCHEMBL28797041 | 1.00 | MAPT (0.43) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| Griffonin SCHEMBL20995242 | 1.00 | MAPT (0.43) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| Griffonin SCHEMBL21034801 | 1.00 | MAPT (0.43) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL21035198 | 0.92 | PTPN1 (0.35) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL29586077 | 0.89 | PTPN1 (0.40) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL21035195 | 0.80 | PTPN1 (0.45) | PTPN1L3MBTL1MEN1KMT2ATYR | |
| SCHEMBL30615017 | 0.79 | PTPN1 (0.44) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL30089929 | 0.79 | PTPN1 (0.44) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL21034846 | 0.79 | L3MBTL1 (0.42) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| Trehalose SCHEMBL166078 | 0.69 | MAPT (0.56) | MAPTPTPN1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090605-A2 | COMPOSITIONS AND METHODS COMPRISING TARGETED LIPOSOMAL THERAPEUTIC VACCINES | DREXEL UNIVERSITY (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4689670-A1 | METHOD FOR IDENTIFYING REACTIVE OXYGEN SPECIES | Centre National de la Recherche Scientifique (FR) | 2026-02-11 | — | — | EP | disclosed |
| CN-120983453-A | Application of small molecular antioxidant in slowing down vascular injury of type 2 diabetes | 深圳市中佳生物医疗科技有限公司 | 2025-11-21 | — | — | CN | disclosed |
| WO-2025133028-A1 | COMBINATION OF A BMP AND BMP2 L51P | Universität Bern (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574164-A1 | COMBINATION OF A BMP AND BMP2 L51P | Universität Bern (CH) | 2025-06-25 | — | — | EP | disclosed |
| US-12266425-B1 | T cell receptor sequences diagnostic for COVID-19 and related compositions | ADAPTIVE BIOTECHNOLOGIES CORPORATION (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024200474-A1 | METHOD FOR IDENTIFYING REACTIVE OXYGEN SPECIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-10-03 | — | — | WO | disclosed |
| EP-4439067-A1 | METHOD FOR IDENTIFYING REACTIVE OXYGEN SPECIES | Centre National de la Recherche Scientifique (FR) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294513-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | 712 NORTH INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-11993590-B2 | Pyranone compounds useful to modulate OMA1 protease | 712 NORTH INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4132577-A2 | VACCINES, ADJUVANTS, AND METHODS OF GENERATING AN IMMUNE RESPONSE | Eisai R&D Management Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| CN-112368280-B | Heterocyclic derivatives as pest control agents | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-115146034-A | Data balancing processing method based on syntactic analysis and synonym replacement technology | 西安理工大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-110505884-B | Anti-cancer combination therapy | 勃林格殷格翰国际有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114554887-A | Smoking substitute system | 聂鲁达有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220111004-A1 | Combinatorial Apparatus for Disease Management | MANYAK DAVID M (US) | 2022-04-14 | — | — | US | disclosed |
| WO-2022039259-A1 | METHOD FOR INDUCING IMMUNITY TO SARS-CoV-2 | 国立研究開発法人理化学研究所 | 2022-02-24 | — | — | WO | disclosed |
| CN-114072495-A | Modified immune cells with enhanced antitumor activity and immunosuppressive resistance | 比姆医疗股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11179408-B2 | Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes | UNIVERSITÉ DE GENÈVE (CH) | 2021-11-23 | — | — | US | disclosed |
| US-20190160085-A1 | USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO (BR) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294513-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | PITRM1, OPA1, HTRA2 | MAPT 2058/4885PTPN1 4484/4885L3MBTL1 1875/4885 |
| US-11993590-B2 | Pyranone compounds useful to modulate OMA1 protease | OPA1, OLA1, PITRM1 | MAPT 641/4885PTPN1 3182/4885L3MBTL1 3927/4885 |
| US-20190160085-A1 | USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES | SLC5A1, SLC5A2, GYS2 | MAPT 2428/4885PTPN1 3362/4885L3MBTL1 1912/4885 |
| US-11179408-B2 | Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes | SLC5A2, SLC5A1, GYS2 | MAPT 2343/4885PTPN1 3241/4885L3MBTL1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.